Global /United States /Healthcare /Biotechnology /BNGO
chevron_leftBack
Bionano Genomics, Inc. logo

Bionano Genomics, Inc.

BNGO
NASDAQ: BNGO Delayed
1.16USD -2.5%
As of 14 June 2026, Bionano Genomics, Inc. has a market cap of $12.87M USD, ranking #39905 globally and #5221 in the United States. It ranks #3556 in the Healthcare sector, and #695 in the Biotechnology industry.
Global Rank
39905
Country Rank
5221
Sector Rank
3556
Industry Rank
695
Key Stats
Market Cap
$12.87MUSD
Enterprise Value
$10.44MUSD
Revenue (TTM)
$28.51MUSD
EBITDA (TTM)
-$23.81MUSD
Net Income (TTM)
-$26.4MUSD
EBITDA Margin
-84%
Profit Margin
-93%
PS Ratio
0.4
PB Ratio
0.3
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Biotechnology
CEO
Robert Holmlin open_in_new
Employees
97
Founded
2003
IPO
21 Aug 2018
Website
bionano.com open_in_new
1d 1w 1m 3m 6m 1y
-2.5% -7.2% -8.7% -23% -38% -73%

News

Loading...

BNGO Analyst Forecasts

Loading...

Markets

Exchange Ticker Price
NASDAQ
MIC: XNAS
PRIMARY
BNGO
Bionano Genomics Inc
ISIN: US09075F4046
Shares Out.:
11.475M1 Shares Float: 10.784M2
TV:
SA:
YF:
GF:
NQ:
BA:
MS:
1.16 USD
London Stock Exchange
MIC: XLON
0A4K
Bionano Genomics Inc
ISIN: US09075F4046
Shares Out.:
4.681M1 Shares Float: 4.664M2
TV:
SA:
YF:
GF:
BA:
MS:
5.26 USD
Mexican Bolsa
MIC: XMEX
BNGO
Bionano Genomics Inc
ISIN: US09075F4046
TV:
SA:
YF:
GF:
BA:
MS:
21.06 MXN
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.

About Bionano Genomics, Inc.

Bionano Genomics, Inc., together with its subsidiaries, provides genome analysis solutions in the Americas, Europe, the Middle East, Africa, China, Japan, South Korea, Singapore, India, and Australia. The company offers genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It also provides Saphyr and Stratys systems, which are sample-to-result solutions for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr and Stratys instruments, which are single-molecule imagers; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA; and Ionic purification system, which isolates and purifies nucleic acid molecules. In addition, the company offers Saphyr, Stratys, and Bionano compute servers; and VIA software, which offers one solution for solutions for cytogenetics and molecular genetics. Further, it provides testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; OGM-Dx HemeOne testing; OGM-Dx FSHD, a test for individuals suspected of having FSHD type 1; and OGM-Dx Postnatal Whole Genome SV and OGM-Dx Prenatal Whole Genome SV for comprehensive testing. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.

Similar Companies

Industry: Biotechnology (United States)
Name
Market Cap diff.
PE
AMGN
$182.42B
1M%
23.9
GILD
$159.92B
1M%
19.0
NTRA
$27.6B
214K%
-
$26.3B
204K%
20.0
$25.03B
194K%
20.4
MRNA
$18.13B
141K%
-
Industry: Biotechnology (Global)
Name
Market Cap diff.
PE
ARGX
$47.84B
41.39B EUR
372K%
39.9
$44.84B
68.19T KRW
348K%
35.5
CSL
$42.36B
60.27B AUD
329K%
29.3
LONN
$42.3B
33.71B CHF
329K%
37.2
068270
$28.11B
42.76T KRW
218K%
43.8
BNTX
$25.69B
200K%
-
chevron_leftBack